Study Comparing Muraglitazar With Glimepiride in Type 2 Diabetics Who Are Not Controlled With Metformin Alone

• Status: Completed
• Trial end date: 2006-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this clinical research study is to learn whether a muraglitazar-metformin combination is at least as effective as a glimepiride-metformin combination to treat type 2 diabetics who are not sufficiently controlled with metformin alone. The safety of this treatment will also be studied.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bristol-Myers Squibb
• Collaborator: Merck Sharp & Dohme Corp.
• Treatments: Glimepiride; Glycine; Metformin

Criteria

Inclusion Criteria:

• Subject with Type 2 diabetes receiving treatment with at least 1,500 mg but not greater than 3000 mg of stable metformin therapy for at least 6 weeks prior to screening

• HbA1c >or = 7% and < or = 10%

• Fasting c-peptide > or = 1.0 umol

• Body Mass Index < or = 41 kg/m2

• Mean serum triglycerides < or = 600 mg/dl